The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The role of novel therapies in R/R DLBCL
In this video, Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses novel targeted therapies and their role in the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Osborne first mentions the excitement surrounding the use of chimeric antigen receptor T-cell (CAR-T) therapy in R/R DLBCL, and briefly highlights the promising results obtained in the ZUMA-7 trial (NCT03391466). Following this, Dr Osborne mentions the importance of ensuring that treatment is applied in a real-world setting to the same patient population as those in the clinical trial setting. Dr Osborne then discusses the promise of other targeted therapies, including tafasitamab plus lenalidomide, and their role in the treatment of relapsed disease. To conclude, Dr Osborne highlights the excitement around bispecific antibodies and their future role in the treatment of R/R DLBCL, and the need to better understand durability and toxicity associated with these agents. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
